ROMAS study: An intestinal microbiome intervention affects biochemical disease activity in patients with antiphospholipid syndrome

Aim of this study was to evaluate whether the gut microbiome affects disease activity in human APS. 15 APS patients with stable disease received oral vancomycin, 500mg four times daily for seven days.
Disease activity was assessed at four time points by measuring a panel of clinical phenotype-related biomarkers: antiphospholipid antibodies (APLAs), complement and inflammation markers and hemostatic parameters. The primary outcome was change from baseline in the composite of the biomarker panel determined by multi-level principal component analysis.